Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 27, 2023
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trialSaskia A Cooke, Dirk de Ruysscher, Bart Reymen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2021
The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body RadiotherapyKarin Lindberg, Vitali Grozman, Kristin Karlsson, et al.International Journal of Radiation Oncology, Biology, Physics|July 27, 2025
Stereotactic Ablative Radiation Therapy of Bone Metastases in an Oligometastatic Setting: One-Year Follow-Up of the BONY-M Phase 2 TrialNicklas Juel Spindler, Mette van Overeem Felter, Olfred Hansen, et al.International Journal of Radiation Oncology, Biology, Physics|July 9, 2023
Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung TumorsSara Lindberg, Vitali Grozman, Kristin Karlsson, et al.International Journal of Radiation Oncology, Biology, Physics|January 14, 2026
Dose-Volume Predictors of Fatal Bronchopulmonary Bleeding After Stereotactic Body Radiation Therapy of Centrally Located Lung Tumors: An Analysis of the Expanded HILUS CohortKristin Karlsson, Tiziana Rancati, Elias Lindbäck, et al.Lung Cancer (Amsterdam, Netherlands)|April 4, 2025
Stereotactic body radiation therapy (SBRT) of centrally located medically inoperable early-stage non-small cell lung cancer (T1-T3N0M0) - A subgroup analysis of the expanded HILUS studySara Lindberg, Vitali Grozman, Kristin Karlsson, et al.European Journal of Cancer (Oxford, England : 1990)|June 12, 2026
Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLCRikke Andersen, Mette Syberg Jespersen, Mario Presti, et al.The Lancet. Oncology|April 30, 2026
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortiumJoachim Widder, Guus M Bol, Inga-Malin Simek, et al.Pageof 4